Bioasis (TSXV:BTI; OTCQB:BIOAF), a biopharmaceutical company, has the potential to transform the treatment of brain disorders by bringing new, innovative technologies to the forefront. Their scientific research has led to a technology that transports medicine across the blood-brain barrier to offer a more successful treatment for diseases of the central nervous system. With statistics showing that 1 in 6 people acquiring a neurological disease, the work done by Bioasis is both necessary and lifesaving. Through the forward-thinking and industry-leading work of Bioasis, patients have the opportunity to overcome illness and live a healthier tomorrow. Bioasis has worked diligently to grow investment opportunities while focusing on research and development to treat neurological diseases and disorders. The biopharmaceutical company works towards cures for brain cancers, metabolic disorders, and neurodegenerative diseases amongst other brain conditions. Bioasis has developed and commercialized a proprietary brain delivery technology, the xB3³ platform, to make life-saving drugs brain-penetrant and deliver those therapies at a therapeutically relevant dose. The xB³ platform outperforms all other blood-brain barrier technologies, delivering a greater percentage of injected dose. With several notable milestones under its belt, Bioasis formed a strategic partnership with Chiesi Group on June 29, 2020. This unique, medically-based partnership has provided a budding investment opportunity for those looking to invest. Their alliance validates the innovative xB³ platform and provides Chiesi Group with an exclusive license to use the xB³ platform to deliver enzymes to treat four metabolic disorders known as lysosomal storage disorders. As a result of Chiesi Group’s exclusive access to Bioasis’ research and technology, the Company received an upfront payment of US$3 million. Up to US$138 million in potential milestone payments and royalties on licensed product sales are also part of the deal. This mutually beneficial deal will allow Bioasis to further their research and technology while offering their groundbreaking blood-brain barrier technologies to other potential partners for the development of treatments for other life-threatening conditions beyond the four lysosomal storage disorders that form part of the Chiesi deal. Bioasis’ partnership or joint venture-based business strategy not only offers potentially improved overall health outcomes for patients, it offers the opportunity for Bioasis to expand the adoption of their technology and to invest in the industry-leading research within its own internal pipeline which encompasses potentially blockbuster new drugs. Bioasis’ opportunity for growth, strategic partnerships with medical masterminds, and innovation within the biopharmaceutical market presents an exciting new prospect for potential investors.
